Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis

H. Lastuvkova, FA. Faradonbeh, J. Schreiberova, M. Hroch, J. Mokry, H. Faistova, Z. Nova, R. Hyspler, IC. Igreja Sa, P. Nachtigal, A. Stefela, P. Pavek, S. Micuda

. 2021 ; 22 (12) : . [pub] 20210616

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025569

Grantová podpora
Progres Q40/05 Grantová Agentura, Univerzita Karlova
260543/2020 Grantová Agentura, Univerzita Karlova
260 549 Grantová Agentura, Univerzita Karlova
GAUK 3462/18 Grantová Agentura, Univerzita Karlova
GACR 19-14497S Grantová Agentura České Republiky
INOMED (CZ.02.1.01/0.0/0.0/18_069/0010046) Ministerstvo Školství, Mládeže a Tělovýchovy

Bile acids (BA) play a significant role in the pathophysiology of nonalcoholic steatohepatitis (NASH). The present study evaluates the modulation of bile acid metabolomics by atorvastatin, a cholesterol-lowering agent commonly used to treat cardiovascular complications accompanying NASH. NASH was induced in mice by 24 weeks of consuming a high-saturated fat, high-fructose, and high-cholesterol diet (F), with atorvastatin administered orally (20 mg/kg/day) during the last three weeks. Biochemical and histological analyses confirmed the effectiveness of the F diet in inducing NASH. Untreated NASH animals had significantly reduced biliary secretion of BA and increased fecal excretion of BA via decreased apical sodium-dependent bile salt transporter (Asbt)-mediated reabsorption. Atorvastatin decreased liver steatosis and inflammation in NASH animals consistently with a reduction in crucial lipogenic enzyme stearoyl-coenzyme A (CoA) desaturase-1 and nuclear factor kappa light chain enhancer of activated B-cell pro-inflammatory signaling, respectively. In this group, atorvastatin also uniformly enhanced plasma concentration, biliary secretion and fecal excretion of the secondary BA, deoxycholic acid (DCA). However, in the chow diet-fed animals, atorvastatin decreased plasma concentrations of BA, and reduced BA biliary secretions. These changes stemmed primarily from the increased fecal excretion of BA resulting from the reduced Asbt-mediated BA reabsorption in the ileum and suppression of synthesis in the liver. In conclusion, our results reveal that atorvastatin significantly modulates BA metabolomics by altering their intestinal processing and liver synthesis in control and NASH mice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025569
003      
CZ-PrNML
005      
20211026133703.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22126468 $2 doi
035    __
$a (PubMed)34208774
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lastuvkova, Hana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic
245    10
$a Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis / $c H. Lastuvkova, FA. Faradonbeh, J. Schreiberova, M. Hroch, J. Mokry, H. Faistova, Z. Nova, R. Hyspler, IC. Igreja Sa, P. Nachtigal, A. Stefela, P. Pavek, S. Micuda
520    9_
$a Bile acids (BA) play a significant role in the pathophysiology of nonalcoholic steatohepatitis (NASH). The present study evaluates the modulation of bile acid metabolomics by atorvastatin, a cholesterol-lowering agent commonly used to treat cardiovascular complications accompanying NASH. NASH was induced in mice by 24 weeks of consuming a high-saturated fat, high-fructose, and high-cholesterol diet (F), with atorvastatin administered orally (20 mg/kg/day) during the last three weeks. Biochemical and histological analyses confirmed the effectiveness of the F diet in inducing NASH. Untreated NASH animals had significantly reduced biliary secretion of BA and increased fecal excretion of BA via decreased apical sodium-dependent bile salt transporter (Asbt)-mediated reabsorption. Atorvastatin decreased liver steatosis and inflammation in NASH animals consistently with a reduction in crucial lipogenic enzyme stearoyl-coenzyme A (CoA) desaturase-1 and nuclear factor kappa light chain enhancer of activated B-cell pro-inflammatory signaling, respectively. In this group, atorvastatin also uniformly enhanced plasma concentration, biliary secretion and fecal excretion of the secondary BA, deoxycholic acid (DCA). However, in the chow diet-fed animals, atorvastatin decreased plasma concentrations of BA, and reduced BA biliary secretions. These changes stemmed primarily from the increased fecal excretion of BA resulting from the reduced Asbt-mediated BA reabsorption in the ileum and suppression of synthesis in the liver. In conclusion, our results reveal that atorvastatin significantly modulates BA metabolomics by altering their intestinal processing and liver synthesis in control and NASH mice.
650    _2
$a zvířata $7 D000818
650    _2
$a atorvastatin $x farmakologie $7 D000069059
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a biologické markery $7 D015415
650    _2
$a dieta s vysokým obsahem tuků $7 D059305
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a homeostáza $7 D006706
650    _2
$a statiny $x farmakologie $7 D019161
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a myši $7 D051379
650    _2
$a biologické modely $7 D008954
650    _2
$a nealkoholová steatóza jater $x farmakoterapie $x etiologie $x metabolismus $x patologie $7 D065626
650    _2
$a triglyceridy $x biosyntéza $7 D014280
655    _2
$a časopisecké články $7 D016428
700    1_
$a Faradonbeh, Fatemeh Alaei $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Schreiberova, Jolana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Hroch, Milos $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Mokry, Jaroslav $u Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Faistova, Hana $u The Fingerland Department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Nova, Zuzana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Hyspler, Radomír $u Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Igreja Sa, Ivone Cristina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Stefela, Alzbeta $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 12 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34208774 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133709 $b ABA008
999    __
$a ok $b bmc $g 1714565 $s 1146076
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 12 $e 20210616 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a Progres Q40/05 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a 260543/2020 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a 260 549 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a GAUK 3462/18 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a GACR 19-14497S $p Grantová Agentura České Republiky
GRA    __
$a INOMED (CZ.02.1.01/0.0/0.0/18_069/0010046) $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace